Atlas Trials

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Clinical trial NCT03003546 · COMPLETED

Trial details

NCT number
NCT03003546
Sponsor
Mayo Clinic
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Aggressive Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Small Lymphocytic Lymphoma
Start date
2019-04-25
Primary completion
2023-05-16
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.